Novartis Stock Falls After Clinical Trial Failure

Novartis shares dropped significantly after another key late-stage drug trial missed its targets, raising questions about the company's growth projections.

10 Sept, 19:17 — 10 Sept, 19:17

Post Share

Sources

Showing 1 of 1 sources

thestreet1d ago

Novartis stock in hot water after another key failure

The drugmaker saw its second late-stage trial miss in days, and Wall Street is now questioning its growth targets.

By Peace Longe

Read full article →

Novartis Stock Falls After Clinical Trial Failure

Sources

Novartis stock in hot water after another key failure

Related Stories

Saudi Arabia Shuts Key Pipeline After Drone Attacks From Iraq

Economic Concerns Challenge Trump's Agenda Amid Rising Oil Prices

Trump Administration Lends $100M to African Cell Network

Justin Trudeau Launches Entertainment Production Company